Name
Boundless Bio
Company Description
Boundless Bio is a clinical-stage precision oncology company addressing unmet needs of patients with oncogene-amplified cancers driven by extra-chromosomal DNA (ecDNA). Our lead investigational ecDNA-directed therapy is BBI-355, an oral CHK1 inhibitor in Phase 1/2 (POTENTIATE, NCT05827614), that is being tested as monotherapy and in combination with targeted agents.
Website
Address (city, state, and country will display online and in-print)
San Diego, CA
United States
United States